Signaling pathways downstream to receptor tyrosine kinases: targets for cancer treatment

Abstract

Mammalian cells have the ability to respond to a myriad of diverse extracellular stimuli that modulate cell function. This often involves ligands binding to cell surface receptors and subsequent activation of intracellular signaling pathways. These pathways can lead to changes in gene expression patterns that in turn regulate cell growth, differentiation, migration, and function. One important type of cell surface receptor is the receptor tyrosine kinase (RTK). In response to in response to ligand binding, RTKs dimerize, then trans-phosphorylate each other, leading to activation of downstream pathways. While the signaling proteins in these pathways are important for normal cell growth control, when improperly regulated they can lead to uncontrolled growth and sometimes cancer. For this reason, they are often considered to be good candidates for drug targets for chemotherapeutic drugs. RTKs can activate multiple different signaling pathways. Some of the signaling proteins in these pathways can have crosstalk with other RTK activated pathways, and some of them can be activated by multiple mechanisms in addition to activation by RTKs. While there is a wide array of different signaling proteins and pathways activated by RTKs, in this review we will discuss components of several key pathways including the MAPK pathway, the Her2/Neu pathway, mTOR, and Pak kinases. We provide an overview of the roles for these pathways in cell signaling and discuss how different components of these pathways are being considered as targets for cancer treatment.

Invasion and Metastasis as a Central Hallmark of Breast Cancer

“…HER2 amplification or protein overexpression is found in 20-30% of invasive breast cancers and is associated with accelerated cell growth, proliferation and poor clinical outcomes [18,19]. One of the most common inhibitors of HER2 is trastuzumab, a monoclonal antibody that binds to the extracellular domain of HER2 and inhibits several major downstream signaling pathways that regulate tumor growth, such as the RAS/RAF/MEK/MAPK and the PI3K/AKT pathways [20,21]. In addition to activation by homodimerization, enhanced by overexpression of the receptor in breast cancer, HER2 can dimerize with other ErbB family members such as the epidermal growth factor receptor (EGFR).…”

Licoflavone A Suppresses Gastric Cancer Growth and Metastasis by Blocking the VEGFR-2 Signaling Pathway

“…Tyrosine kinases play an essential role in tumorigenesis and development and are targets of antitumor therapy. At present, the mechanism of action of small-molecule inhibitors targeting tyrosine kinase activity is mostly by blocking the activation of receptor tyrosine kinases [ 45 ]. VEGFR-2 is an essential member of the tyrosine kinase family.…”

Exploring the Gamut of Receptor Tyrosine Kinases for Their Promise in the Management of Non-Alcoholic Fatty Liver Disease

“…Broadly speaking, RTKs play a significant function in intra-cellular signaling and cell-to-cell communication. They respond to external signals such as growth factors and initiate a cascade of intracellular responses that regulate cell growth, proliferation, differentiation, motility, and other cell-type specific functions [ 30 , 31 ]. Individual cells and tissues in the organism exhibit tight regulation of RTKs via expression and phosphorylation-mediated controls.…”